Voyager Therapeutics Inc. (VYGR) Upgraded by Zacks Investment Research to “Buy”
Zacks Investment Research upgraded shares of Voyager Therapeutics Inc. (NASDAQ:VYGR) from a hold rating to a buy rating in a research note published on Wednesday. They currently have $13.00 price target on the stock.
According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
Other analysts have also issued research reports about the company. Piper Jaffray Cos. set a $37.00 target price on Voyager Therapeutics and gave the stock a buy rating in a report on Thursday, August 11th. Stifel Nicolaus started coverage on Voyager Therapeutics in a report on Thursday, July 14th. They issued a buy rating and a $33.00 target price for the company. Cowen and Company reissued a buy rating on shares of Voyager Therapeutics in a report on Wednesday, June 22nd. Finally, Wedbush reissued an outperform rating and issued a $36.00 target price on shares of Voyager Therapeutics in a report on Thursday, August 11th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $26.80.
Voyager Therapeutics (NASDAQ:VYGR) traded down 0.62% during mid-day trading on Wednesday, hitting $11.20. The company had a trading volume of 1,721 shares. The company’s market capitalization is $299.35 million. Voyager Therapeutics has a 52 week low of $8.12 and a 52 week high of $30.54. The firm’s 50 day moving average is $12.79 and its 200 day moving average is $12.71.
Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Thursday, August 11th. The company reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.03. Voyager Therapeutics had a negative return on equity of 25.13% and a negative net margin of 150.47%. On average, equities research analysts predict that Voyager Therapeutics will post ($1.53) EPS for the current year.
Several large investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Voyager Therapeutics by 1,487.3% in the second quarter. Vanguard Group Inc. now owns 312,593 shares of the company’s stock valued at $3,436,000 after buying an additional 292,900 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Voyager Therapeutics by 171.3% in the second quarter. JPMorgan Chase & Co. now owns 288,425 shares of the company’s stock valued at $3,170,000 after buying an additional 182,125 shares during the period. BlackRock Fund Advisors boosted its stake in shares of Voyager Therapeutics by 106.8% in the second quarter. BlackRock Fund Advisors now owns 302,971 shares of the company’s stock valued at $3,330,000 after buying an additional 156,443 shares during the period. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Voyager Therapeutics during the first quarter valued at about $873,000. Finally, State Street Corp boosted its stake in shares of Voyager Therapeutics by 147.1% in the second quarter. State Street Corp now owns 142,611 shares of the company’s stock valued at $1,565,000 after buying an additional 84,906 shares during the period. 39.66% of the stock is currently owned by hedge funds and other institutional investors.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.
Receive News & Stock Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related stocks with our FREE daily email newsletter.